Company intelligence / Profile preview

Ensemble Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Ensemble Therapeutics pioneered a proprietary DNA-programmed chemistry platform to enable the discovery of 'Ensemblins'—synthetic macrocycles—addressing drug targets traditionally considered undruggable. Their primary indications centered on difficult targets such as protein-protein interactions implicated in cancer, inflammation, and metabolic disease. The company focused mainly on pre-clinical and partnered discovery-stage programs.[1][2][3]

Therapeutic areas: ImmunologyEndocrinologyInfectious DiseasesNeurologyMetabolic DisordersOncology
Modalities: Bicyclic peptidesMacrocycleSmall molecule
Industry: Biotech

Partnerships

PfizerBristol Myers Squibb

Beyond the preview

Go deeper on Ensemble Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ensemble Therapeutics.

Explore the full profile